Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988–1997, 1990.
Rosen G. The current management of malignant bone tumors: Where do we go from here? Med J Austral 148:373–377, 1988.
Winkler K, Bielack S. Chemotherapy of osteosarcoma. Semin Orthop 3:48–58, 1988.
Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma, intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum-II (CDP). Angiographic, pathologic and pharmacologic studies. Cancer 51:402–407, 1983.
Jaffe N, Raymond AK, Ayala A et al. Effect of cumulative courses of intra-arterial cis-diamminedichloroplatinum-II on the primary tumor in osteosarcoma. Cancer 63:63–67, 1989.
Chuang VP, Benjamin RS, Jaffe N, et al. Radiographic and angiographic changes in osteosarcoma after intra-arterial chemotherapy. Am J Roentgenol 239:1065–1069, 1982.
Shirkoda A, Jaffe N, Wallace S, et al. Computed tomography of osteosarcoma following intra-arterial chemotherapy. Am J Roentgenol 144:95–99, 1985.
Pan G, Raymond AK, Carrasco CH, et al. Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology —:517–526, 1990.
Jaffe N, Spears R, Eftekhari F, et al. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival. Cancer 59:701–709, 1987.
Jaffe N, et al. Intra-arterial cis-diamminedichloroplatinum-II in the management of Stage II B osteosarcoma in the pediatric and adolescent age group. Clinical Orthop Rel Res, 1991.
Kletzel M, Jaffe N. Systemic hypertension. A complication of intra-arterial cis-diamminedichloroplatinum-II infusion. Cancer 47:245–247, 1981.
Jaffe N, et al. Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma: effect on creatinine clearance and methotrexate excretion. Cancer 59:1577–1581, 1987.
Ruiz L, et al. Auditory function in pediatric osteosarcoma patients treated with multiple courses of cis-diamminedichloroplatinum-II (CDP). Cancer Res 49:742–744, 1989.
Wright KC, et al. Pulsed arterial infusions. Chemotherapeutic complications. Cancer 57:1952–1956, 1986.
Rosen G, Nitenberg A, Caparros B, et al. Cis-platinum in metastatic osteogenic sarcoma. In: Cis-platin: Current Status and New Developments. Prestayko AW, Crooke ST, Carter SK, Eds. Academic Press, New York, 1980, pp 465–475.
Pratt CB, Hayes A, Green AA, et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep 65:1021–1026, 1981.
Sarna G, Skinner DG, Smith RB, et al. Cis-diamminedichloroplatinum (II) alone and in combination in the treatment of testicular and other malignancies. Cancer Treat Rep 64:1077–1082, 1980.
Ochs JL, Freeman AI, Douglass HO, Jr., et al. Cis-dichlorodiammine-platinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62:239–245, 1978.
Freeman AI, Ettinger LJ, Brecher ML. cis-dichlorodiammine-platinum II in childhood cancer. Cancer Treat Rep 63:1615–1620, 1979.
Baum ES, Gaynon P, Greenburg L, et al. Phase II trials of cisplatin in refractory childhood cancer: children’s cancer study group report. Cancer Treat Rep 65:815–822, 1981.
Nitschke R, Fagundo R, Berry DH, Falletta JM. Weekly administration of cis-dichloro-diammineplatinum (II) in childhood solid tumors. A Southwest Oncology Group study. Cancer Treat Rep 63:497–499, 1979.
Gasparini M, Rouesse J, van Ooster A, et al. Phase II study of cis-platin in advanced osteogenic sarcoma. Cancer Treat Rep 69:211–213, 1985.
Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 67:126–134, 1991.
Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma. Results of a cooperative German/Austrian study. J Clin Oncol 2:617–624, 1984.
Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Results of a randomized cooperative trial (COSS-82) with salvage. Chemotherapy based on histological tumor response. J Clin Oncol 6:329–337, 1988.
Winkler K, Bielack S, Delling G, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin high dose methotrexate and ifosfamide on histologic tumor response in osteosarcoma. Cancer 66:1703–1710, 1990.
Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high dose methotrexate, cisplatinum and doxorubicin for management of patients with nonmetastatic osteosarcoma. Cancer Treat Rep 70:1431–1432, 1986.
Benjamin RS, Chawla SP, Murray J, et al. Preoperative chemotherapy for osteosarcoma: a treatment approach facilitating limb salvage with major prognostic indications. In: Adjuvant Therapy of Cancer IV. Jones SF, Salmon SE, Eds. Grune and Stratton, Philadelphia, 1984, pp 601–610.
Picci P, Bacci G, Compana R, et al. Neoadjuvant chemotherapy for osteosarcoma. Results of a prospective study. In: Recent Concepts in Sarcoma Treatment. Ryan JR, Baker LO, Eds. Kluwer Academic Publishers, Boston, 1987, pp 291–295.
Stine KC, Hockenberry MJ, Horrelson J, et al. Systemic doxorubicin and intra-arterial cisplatin preoperative chemotherapy plus post-operative adjuvant chemotherapy in patients with osteosarcoma. Cancer 63:848–853, 1989.
Graham-Pole J, Saleh R, Springfield D, et al. Neoadjuvant chemotherapy for limb osteosarcoma. In: Neoadjuvant Chemotherapy, Vol 169. Jacqultat CL, Weil M, Khayat D, Eds. John Libbey Eurotext, 1988, pp 615–520.
Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504, 1984.
Bielack S, Erttman R, Looft G, et al. Platinum disposition after intra-arterial and intravenous infusions of cisplatinum for osteosarcoma. Cancer Chemother Pharmacol 24:376–380, 1989.
Campbell TN, et al. Clinical pharmacokinetics of intra-arterial cisplatin in humans. J Clin Oncol 1:755–762, 1983.
Oldfield EH, Clark WC, Dedrick RL, et al. Reduced systemic drug exposure by combining intra-arterial cis-diamminedichloroplatinum (II) with hemodialysis of regional venous drainage. Cancer Res 47:1962–1967, 1987.
Stewart DJ, Benjamin RS, Zimmerman S, et al. Clinical pharmacology of intra-arterial cis-diamminedichloroplatinum (II). Cancer Res 43:917–920, 1983.
Jaffe N, Frei E III, Traggis D, Watts, H. Weekly high dose methotrexate citrovorum factor in osteogenic sarcoma: presurgical treatment of primary tumor and of overt pulmonary metastases. Cancer 39:45–50, 1977.
Jaffe N, Raymond K, Ayala A, et al. Analysis of the efficacy of intra-arterial cis-diamminedichloroplatinum-II and high dose methotrexate with citrovorum factor rescue in the treatment of primary osteosarcoma. Res Cancer Treat 2:157–163, 1989.
Link MP, Goorin MA, Miser AW, et al. The effect of adjuvant chemotherapy on relaspe-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606, 1986.
Rosen G. Neoadjuvant chemotherapy for osteogenic sarcoma. A model for the treatment of other highly malignant neoplasms. Rec Res Cancer Res 103:148–157, 1986.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jaffe, N. (1993). Pediatric osteosarcoma: Treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)— Advantages, disadvantages, and controversial issues. In: Humphrey, G.B., Koops, H.S., Molenaar, W.M., Postma, A. (eds) Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Cancer Treatment and Research, vol 62. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3518-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3518-8_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6561-7
Online ISBN: 978-1-4615-3518-8
eBook Packages: Springer Book Archive